Boris Alexandrovich Neymark
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Boris Alexandrovich Neymark has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Izrailevich Neymark
Altai State Medical University
19 shared publications - Nikolai Alexandrovich Nozdrachev
Altai State Medical University
11 shared publications - Sergey V. Popov
St. Luka’s Clinical Hospital; S. M. Kirov Military Medical Academy, Russian Ministry of Defense of Russia; St. Petersburg Medical and Social Institute
11 shared publications - Igor N. Orlov
St. Luke’s Saint Petersburg Clinical Hospital; Mechnikov North-Western State Medical University
7 shared publications - Evgenii V. Pomeshkin
Kemerovo State University
5 shared publications - Timur M. Topuzov
St. Luke's Clinical Hospital, St. Petersburg
5 shared publications
Latest Publications
- 22 October 2026
- Published by ECO-Vector LLC (Publications) in Urology Reports (St. - Petersburg)
- Vol. 16 (3) , 313-321
Clinical and instrumental factors influencing the choice of surgical treatment for benign prostatic hyperplasia: a comparative analysis of prostate transurethral resection, transurethral enucleation, and prostatic artery embolization
BACKGROUND:The selection of an appropriate surgical treatment for benign prostatic hyperplasia remains a significant challenge in contemporary urology. Despite the availability of clinical guidelines, the decision between transurethral resection of the prostate (TURP), transurethral enucleation of the prostate (TUEP), and prostatic artery embolization (PAE) is often based on a comprehensive assessment of patients’ clinical and instrumental characteristics. AIM:To identify clinical and instrumental factors associated with the choice of surgical treatment method for patients with benign prostatic hyperplasia during transurethral resection of the prostate, transurethral enucleation of the prostate, and embolization of prostatic arteries. METHODS:A retrospective multi-center study was conducted including 150 patients with benign prostatic hyperplasia. TURP was performed in 40 patients, TUEP in 41 patients, and PAE in 69 patients. The following variables were analyzed: patient age, prostate-specific antigen level, prostate volume, uroflowmetry parameters (Qmax and Qav), postvoid residual urine volume, and anesthetic risk according to the American Society of Anesthesiologists (ASA) classification. Intergroup differences were assessed using parametric statistical methods and multivariable regression analysis. RESULTS:Comparative analysis demonstrated statistically significant differences between the groups in prostate-specific antigen levels (p= 0.002) and prostate volume (p 0.001). The largest prostate volume was observed in the PAE group (151.3 ± 70.6 cm3), whereas the corresponding values in the TURP and TUEP groups were 75.0 ± 26.2 cm3and 82.0 ± 30.9 cm3, respectively. No significant differences were found regarding urodynamic parameters, postvoid residual urine volume, or anesthetic risk (p 0.05). Multivariable analysis identified prostate volume as the only independent predictor of PAE selection (odds ratio 1.04, 95% CI 1.01–1.08,p= 0.003). CONCLUSION:Prostate volume is the key independent factor influencing the choice of surgical treatment modality for patients with benign prostatic hyperplasia in real-world clinical practice. These findings support the possibility of objectifying the treatment selection process and may contribute to the development of clinical decision-support systems.
- 22 October 2026
- Published by ECO-Vector LLC (Publications) in Urology Reports (St. - Petersburg)
- Vol. 16 (3) , 313-321
Clinical and instrumental factors influencing the choice of surgical treatment for benign prostatic hyperplasia: a comparative analysis of prostate transurethral resection, transurethral enucleation, and prostatic artery embolization
BACKGROUND:The selection of an appropriate surgical treatment for benign prostatic hyperplasia remains a significant challenge in contemporary urology. Despite the availability of clinical guidelines, the decision between transurethral resection of the prostate (TURP), transurethral enucleation of the prostate (TUEP), and prostatic artery embolization (PAE) is often based on a comprehensive assessment of patients’ clinical and instrumental characteristics. AIM:To identify clinical and instrumental factors associated with the choice of surgical treatment method for patients with benign prostatic hyperplasia during transurethral resection of the prostate, transurethral enucleation of the prostate, and embolization of prostatic arteries. METHODS:A retrospective multi-center study was conducted including 150 patients with benign prostatic hyperplasia. TURP was performed in 40 patients, TUEP in 41 patients, and PAE in 69 patients. The following variables were analyzed: patient age, prostate-specific antigen level, prostate volume, uroflowmetry parameters (Qmax and Qav), postvoid residual urine volume, and anesthetic risk according to the American Society of Anesthesiologists (ASA) classification. Intergroup differences were assessed using parametric statistical methods and multivariable regression analysis. RESULTS:Comparative analysis demonstrated statistically significant differences between the groups in prostate-specific antigen levels (p= 0.002) and prostate volume (p 0.001). The largest prostate volume was observed in the PAE group (151.3 ± 70.6 cm3), whereas the corresponding values in the TURP and TUEP groups were 75.0 ± 26.2 cm3and 82.0 ± 30.9 cm3, respectively. No significant differences were found regarding urodynamic parameters, postvoid residual urine volume, or anesthetic risk (p 0.05). Multivariable analysis identified prostate volume as the only independent predictor of PAE selection (odds ratio 1.04, 95% CI 1.01–1.08,p= 0.003). CONCLUSION:Prostate volume is the key independent factor influencing the choice of surgical treatment modality for patients with benign prostatic hyperplasia in real-world clinical practice. These findings support the possibility of objectifying the treatment selection process and may contribute to the development of clinical decision-support systems.
- 26 May 2026
- Published by PANORAMA Publishing House in Spravočnik vrača obŝej praktiki (Journal of Family Medicine)
- No. 5,p. 52-61
Analysis of a neural network algorithm for selecting a surgery method for benign prostatic hyperplasia: comparison with real clinical tactics
Benign prostatic hyperplasia (BPH) remains one of the most common chronic urological diseases in older men and a leading cause of lower urinary tract symptoms. A neural network algorithm for supporting the choice of surgical treatment for BPH has demonstrated high accuracy, clinical validity, and practical applicability. The algorithm improves the objectivity and reproducibility of medical decisions, reduces the risk of complications, and optimizes patient routing already during the outpatient examination. Integrating such a tool into a medical information system appears to be a promising direction for the digitalization of urological care. Further development of the model requires an expanded sample and multicenter external validation.
- 26 May 2026
- Published by PANORAMA Publishing House in Spravočnik vrača obŝej praktiki (Journal of Family Medicine)
- No. 5,p. 52-61
Analysis of a neural network algorithm for selecting a surgery method for benign prostatic hyperplasia: comparison with real clinical tactics
Benign prostatic hyperplasia (BPH) remains one of the most common chronic urological diseases in older men and a leading cause of lower urinary tract symptoms. A neural network algorithm for supporting the choice of surgical treatment for BPH has demonstrated high accuracy, clinical validity, and practical applicability. The algorithm improves the objectivity and reproducibility of medical decisions, reduces the risk of complications, and optimizes patient routing already during the outpatient examination. Integrating such a tool into a medical information system appears to be a promising direction for the digitalization of urological care. Further development of the model requires an expanded sample and multicenter external validation.
- 31 March 2026
- Published by ECO-Vector LLC (Publications) in Urology Reports (St. - Petersburg)
- Vol. 16 (1) , 81-88
Psychoemotional status and quality of life of patients after radical prostatectomy depending on the methods of treatment of erectile dysfunction
BACKGROUND: Given the high efficacy of medical treatment for erectile dysfunction, active discussions continue regarding the optimal timing for prosthesis implantation after radical prostatectomy. Aim: This study aimed to compare the efficacy of early surgical and conservative treatment of erectile dysfunction in patients after radical prostatectomy. Methods: The study included 53 patients with erectile dysfunction who had undergone radical prostatectomy for localized prostate cancer. All patients began taking phosphodiesterase type 5 inhibitors immediately after surgery. The main group (n = 19) consisted of patients with insufficient efficacy of medical therapy for erectile dysfunction, who underwent penile prosthesis implantation within 1 year after radical prostatectomy, but not earlier than 3 months post-surgery. Patients in the control group (n = 34) continued conservative therapy. At 3 months, 1 year, and 1.5 years after radical prostatectomy, patients were assessed for erectile function using the IIEF-5 questionnaire, quality of life using the SF-36 questionnaires, and levels of anxiety and depression using the Beck and Spielberger–Hanin questionnaires. Results: Analysis of psychoemotional status over time at 1 year after radical prostatectomy showed that patients in the prosthesis group had significantly lower depression scores (p = 0.001) and reactive anxiety (p = 0.03) compared to patients in the control group. This trend between the patient groups persisted at 1.5 years (p = 0.001). The quality of life of patients after prosthesis implantation was also higher at 1 year after radical prostatectomy compared with the control group. This trend between the groups also persisted at 1.5 years. The study data demonstrated that prosthesis implantation significantly improved patients’ erectile function, assessed by IIEF-5, unlike patients in the control group. Conclusion: Penile prosthesis implantation within a year after radical prostatectomy in patients with severe erectile dysfunction is an effective and safe alternative for treating erectile dysfunction as the primary method after 3 months of ineffective medical treatment, with a good level of patient satisfaction and improvement in their psychoemotional status and quality of life.
- 31 March 2026
- Published by ECO-Vector LLC (Publications) in Urology Reports (St. - Petersburg)
- Vol. 16 (1) , 81-88
Psychoemotional status and quality of life of patients after radical prostatectomy depending on the methods of treatment of erectile dysfunction
BACKGROUND: Given the high efficacy of medical treatment for erectile dysfunction, active discussions continue regarding the optimal timing for prosthesis implantation after radical prostatectomy. Aim: This study aimed to compare the efficacy of early surgical and conservative treatment of erectile dysfunction in patients after radical prostatectomy. Methods: The study included 53 patients with erectile dysfunction who had undergone radical prostatectomy for localized prostate cancer. All patients began taking phosphodiesterase type 5 inhibitors immediately after surgery. The main group (n = 19) consisted of patients with insufficient efficacy of medical therapy for erectile dysfunction, who underwent penile prosthesis implantation within 1 year after radical prostatectomy, but not earlier than 3 months post-surgery. Patients in the control group (n = 34) continued conservative therapy. At 3 months, 1 year, and 1.5 years after radical prostatectomy, patients were assessed for erectile function using the IIEF-5 questionnaire, quality of life using the SF-36 questionnaires, and levels of anxiety and depression using the Beck and Spielberger–Hanin questionnaires. Results: Analysis of psychoemotional status over time at 1 year after radical prostatectomy showed that patients in the prosthesis group had significantly lower depression scores (p = 0.001) and reactive anxiety (p = 0.03) compared to patients in the control group. This trend between the patient groups persisted at 1.5 years (p = 0.001). The quality of life of patients after prosthesis implantation was also higher at 1 year after radical prostatectomy compared with the control group. This trend between the groups also persisted at 1.5 years. The study data demonstrated that prosthesis implantation significantly improved patients’ erectile function, assessed by IIEF-5, unlike patients in the control group. Conclusion: Penile prosthesis implantation within a year after radical prostatectomy in patients with severe erectile dysfunction is an effective and safe alternative for treating erectile dysfunction as the primary method after 3 months of ineffective medical treatment, with a good level of patient satisfaction and improvement in their psychoemotional status and quality of life.
- Open Access
- 1 January 2026
- Published by Altay State Medical University in Bulletin of Medical Science
- Vol. 38 (2) , 5-13
DEVELOPMENT OF A SYSTEM FOR ASSESSING RISK CRITERIA FOR UPPER URINARY TRACT CHANGES AND DETERMINING INDICATIONS FOR DRAINAGE IN PYELONEPHRITIS DURING PREGNANCY
One of the key tasks in practical urology is to develop rational criteria for determining indications for upper urinary tract (UUT) drainage in pregnant women with pyelonephritis, in order to reduce the risk of complications and avoid unnecessary invasive procedures. Objective. To develop tactical approaches to the management and treatment of pregnant women with pyelonephritis and urodynamic disturbances, based on an algorithm and a risk-assessment scale for pathological changes, with determination of indications for UUT drainage. Materials and Methods. In a study conducted at the Republican Scientific Center of Urology of the Ministry of Health of the Kyrgyz Republic from 2019 to 2024, 878 pregnant women at various gestational stages with impaired bladder outflow were examined. UUT interventions were performed in 425 (48.4%) patients: 307 (72.2%) underwent ureteral stenting, and 118 (27.8%) underwent percutaneous puncture nephrostomy (PPN). Conservative treatment was provided to 453 (51.6%) pregnant women. Results. To assess indications for drainage of the intrauterine urinary tract, we developed an algorithm that includes anthropometric data, clinical and laboratory indicators, gestational age, and evidence of pathological changes in the kidneys and ureters. A scoring scale was created to rank the risk of developing uropathic changes in pregnancy-associated pyelonephritis and to guide treatment choices. Based on the total scale score, risk groups for upper urinary tract changes were identified, providing justification for further management and therapy in pyelonephritis during pregnancy. This approach optimized treatment tactics and reduced the number of invasive procedures by 35%. The sensitivity of the scoring scale was 92%, and specificity was 85%. Conclusion. Detection of urodynamic disturbances in pyelonephritis during pregnancy does not always indicate UUT drainage. Implementing a system to assess risk criteria for urinary tract changes and to determine drainage indications in pregnant women with pyelonephritis helps reduce unnecessary surgical interventions and improve the quality of medical care. The scoring scale for assessing the risk of pathological changes in pyelonephritis during pregnancy, based on systematized criteria, provides high sensitivity and specificity in determining the necessity for UUT drainage, confirming its clinical significance.
- 1 January 2026
- Published by Altay State Medical University in Bulletin of Medical Science
- Vol. 38 (2) , 5-13
Open AccessDEVELOPMENT OF A SYSTEM FOR ASSESSING RISK CRITERIA FOR UPPER URINARY TRACT CHANGES AND DETERMINING INDICATIONS FOR DRAINAGE IN PYELONEPHRITIS DURING PREGNANCY
One of the key tasks in practical urology is to develop rational criteria for determining indications for upper urinary tract (UUT) drainage in pregnant women with pyelonephritis, in order to reduce the risk of complications and avoid unnecessary invasive procedures. Objective. To develop tactical approaches to the management and treatment of pregnant women with pyelonephritis and urodynamic disturbances, based on an algorithm and a risk-assessment scale for pathological changes, with determination of indications for UUT drainage. Materials and Methods. In a study conducted at the Republican Scientific Center of Urology of the Ministry of Health of the Kyrgyz Republic from 2019 to 2024, 878 pregnant women at various gestational stages with impaired bladder outflow were examined. UUT interventions were performed in 425 (48.4%) patients: 307 (72.2%) underwent ureteral stenting, and 118 (27.8%) underwent percutaneous puncture nephrostomy (PPN). Conservative treatment was provided to 453 (51.6%) pregnant women. Results. To assess indications for drainage of the intrauterine urinary tract, we developed an algorithm that includes anthropometric data, clinical and laboratory indicators, gestational age, and evidence of pathological changes in the kidneys and ureters. A scoring scale was created to rank the risk of developing uropathic changes in pregnancy-associated pyelonephritis and to guide treatment choices. Based on the total scale score, risk groups for upper urinary tract changes were identified, providing justification for further management and therapy in pyelonephritis during pregnancy. This approach optimized treatment tactics and reduced the number of invasive procedures by 35%. The sensitivity of the scoring scale was 92%, and specificity was 85%. Conclusion. Detection of urodynamic disturbances in pyelonephritis during pregnancy does not always indicate UUT drainage. Implementing a system to assess risk criteria for urinary tract changes and to determine drainage indications in pregnant women with pyelonephritis helps reduce unnecessary surgical interventions and improve the quality of medical care. The scoring scale for assessing the risk of pathological changes in pyelonephritis during pregnancy, based on systematized criteria, provides high sensitivity and specificity in determining the necessity for UUT drainage, confirming its clinical significance.
- Open Access
- 1 January 2026
- Published by Altay State Medical University in Bulletin of Medical Science
- Vol. 38 (2) , 174-183
COMPARATIVE CHARACTERISTICS OF MODERN GRAFT MATERIALS FOR CORPOROPLASTY IN PEYRONIE’S DISEASE
Background. Tunical grafting of the penis, commonly referred to as grafting, is regarded as the preferred surgical treatment for Peyronie's disease, particularly for patients with severe penile deformities. Despite the variety of materials available for grafting, there remains no consensus on the optimal choice of graft. Objective. The aim of this study is to analyze the different types of grafts used in Peyronie's disease and to compare their efficacy and safety. Materials and Methods. A comprehensive search for relevant publications was conducted using the National Library of Medicine in the United States and the Central Scientific Medical Library of the Russian Federation. The keywords used in the search included ''Peyronie's disease'', ''Peyronie'', ''graft'', ''patch'', and ''corporoplasty''. Only original research articles and meta-analyses were considered for inclusion. Ultimately, 77 publications were selected for descriptive analysis. Results. Grafting has proven to be an effective method for correcting penile deformity associated with Peyronie's disease. Numerous materials for corporoplasty have been documented, with most studies indicating comparable efficacy for correcting penile curvature. However, variations in postoperative complication rates, such as erectile dysfunction, recurrence of deformity, and graft fibrosis have been noted. It is recommended to prioritize xenografts and autografts, as they offer an optimal blend of biocompatibility, safety, and satisfactory outcomes. In contrast, the use of synthetic materials in corporoplasty is generally discouraged. Among the graft options, autologous venous grafts, buccal mucosa, tunica vaginalis, bovine pericardium, porcine small intestinal submucosa, and collagen hemostatic sponge have shown the highest success rates, despite reports of unsatisfactory outcomes in some cases. Conclusion. Despite the substantial body of published research, no available graft can be deemed ''ideal'' for all patients. The selection of a graft should be tailored to the individual, taking into consideration factors such as the degree of curvature, plaque size, and the patient's erectile function. Additional prospective randomized studies are warranted to further investigate this matter.
- 1 January 2026
- Published by Altay State Medical University in Bulletin of Medical Science
- Vol. 38 (2) , 174-183
Open AccessCOMPARATIVE CHARACTERISTICS OF MODERN GRAFT MATERIALS FOR CORPOROPLASTY IN PEYRONIE’S DISEASE
Background. Tunical grafting of the penis, commonly referred to as grafting, is regarded as the preferred surgical treatment for Peyronie's disease, particularly for patients with severe penile deformities. Despite the variety of materials available for grafting, there remains no consensus on the optimal choice of graft. Objective. The aim of this study is to analyze the different types of grafts used in Peyronie's disease and to compare their efficacy and safety. Materials and Methods. A comprehensive search for relevant publications was conducted using the National Library of Medicine in the United States and the Central Scientific Medical Library of the Russian Federation. The keywords used in the search included ''Peyronie's disease'', ''Peyronie'', ''graft'', ''patch'', and ''corporoplasty''. Only original research articles and meta-analyses were considered for inclusion. Ultimately, 77 publications were selected for descriptive analysis. Results. Grafting has proven to be an effective method for correcting penile deformity associated with Peyronie's disease. Numerous materials for corporoplasty have been documented, with most studies indicating comparable efficacy for correcting penile curvature. However, variations in postoperative complication rates, such as erectile dysfunction, recurrence of deformity, and graft fibrosis have been noted. It is recommended to prioritize xenografts and autografts, as they offer an optimal blend of biocompatibility, safety, and satisfactory outcomes. In contrast, the use of synthetic materials in corporoplasty is generally discouraged. Among the graft options, autologous venous grafts, buccal mucosa, tunica vaginalis, bovine pericardium, porcine small intestinal submucosa, and collagen hemostatic sponge have shown the highest success rates, despite reports of unsatisfactory outcomes in some cases. Conclusion. Despite the substantial body of published research, no available graft can be deemed ''ideal'' for all patients. The selection of a graft should be tailored to the individual, taking into consideration factors such as the degree of curvature, plaque size, and the patient's erectile function. Additional prospective randomized studies are warranted to further investigate this matter.
- Open Access
- 1 January 2026
- Published by Altay State Medical University in Bulletin of Medical Science
- Vol. 38 (1) , 87-95
NEPHROPROTECTIVE AND LITHOKINETIC THERAPY IN PATIENTS WITH UROLITHIASIS UNDERGOING RETROGRADE PYELOLITHOTRIPSY
In the context of modern medical development, when endoscopic approaches to the treatment of urolithiasis are actively being implemented, therapeutic strategies aimed at evacuating small stones and their fragments from the kidneys and upper urinary tract, as well as nephroprotective measures, are gaining new relevance. The use of herbal preparations with pronounced urolithic and nephroprotective properties is quite promising for the therapy of urolithiasis due to their high efficacy and safety. One of the representatives of this group of drugs is Nephrobiolic. Objective.Evaluation of the efficacy and safety of the Nephrobiolic complex as a lithokinetic and nephroprotective therapy in patients after retrograde pyelolithotripsy. Materials and Methods. The study included 30 patients with stone localization in the renal collecting system. By the method of typological selection, the patients were divided into 2 groups of 15 people each, comparable in age, stone size, and clinical data. All study participants underwent Multislice Computed Tomography (MSCT) of the kidneys with recording of the size, contour of the stone, and its density. The size of the stone did not exceed 10 mm in diameter. The density of the stones ranged from 600 to 1500 HU. All patients underwent scheduled kidney stenting on the affected side 10-12 days prior. As part of inpatient treatment, they underwent laser retrograde pyelolithotripsy. Before the surgery, two days after the surgery, and thirty days after the surgery, all patients underwent the necessary examination. As postoperative therapy, patients received drugs of the following classes: nonsteroidal anti-inflammatory drugs (NSAIDs), uroseptics, antispasmodics, dietary therapy, and, if necessary, antibacterial therapy. Patients in group 2 additionally received Nephrobiolic at 2 capsules 2 times a day for 1 month (5–7 days before surgery + 23–25 days after surgical treatment (pieholithotripsy)), with subsequent follow-up observation for 1 month. Results. The passage of stone fragments after retrograde intrarenal surgery (RIRS) was more effectively observed in the group receiving Nephrobiolic. When assessing the level of urine enzymes (alkaline phosphatase (ALP), lactate dehydrogenase (LDH), gamma-glutamyltransferase (GGT), and leucine aminopeptidase (LAP)) in all patients after lithotripsy, an increase in enzymeuria was noted in both groups, more pronounced in group 1, indicating damage to the kidney cell membranes due to the surgical intervention. When assessing the level of enzymuria in the remote period, in the 2nd group of patients this indicator returned to baseline (pre-intervention) values, in the 1st group – a moderate increase in the level of enzymuria persisted. Conclusion. Nephrobiolic promotes a more effective and less painful expulsion of stone fragments after retrograde pyelolithotripsy. This phytocomplex is capable of protecting kidney tissue from the damaging effects of lithotripsy and is characterized by a high degree of safety, which is very important during nephroprotective and lithokinetic therapy.
- 1 January 2026
- Published by Altay State Medical University in Bulletin of Medical Science
- Vol. 38 (1) , 87-95
Open AccessNEPHROPROTECTIVE AND LITHOKINETIC THERAPY IN PATIENTS WITH UROLITHIASIS UNDERGOING RETROGRADE PYELOLITHOTRIPSY
In the context of modern medical development, when endoscopic approaches to the treatment of urolithiasis are actively being implemented, therapeutic strategies aimed at evacuating small stones and their fragments from the kidneys and upper urinary tract, as well as nephroprotective measures, are gaining new relevance. The use of herbal preparations with pronounced urolithic and nephroprotective properties is quite promising for the therapy of urolithiasis due to their high efficacy and safety. One of the representatives of this group of drugs is Nephrobiolic. Objective.Evaluation of the efficacy and safety of the Nephrobiolic complex as a lithokinetic and nephroprotective therapy in patients after retrograde pyelolithotripsy. Materials and Methods. The study included 30 patients with stone localization in the renal collecting system. By the method of typological selection, the patients were divided into 2 groups of 15 people each, comparable in age, stone size, and clinical data. All study participants underwent Multislice Computed Tomography (MSCT) of the kidneys with recording of the size, contour of the stone, and its density. The size of the stone did not exceed 10 mm in diameter. The density of the stones ranged from 600 to 1500 HU. All patients underwent scheduled kidney stenting on the affected side 10-12 days prior. As part of inpatient treatment, they underwent laser retrograde pyelolithotripsy. Before the surgery, two days after the surgery, and thirty days after the surgery, all patients underwent the necessary examination. As postoperative therapy, patients received drugs of the following classes: nonsteroidal anti-inflammatory drugs (NSAIDs), uroseptics, antispasmodics, dietary therapy, and, if necessary, antibacterial therapy. Patients in group 2 additionally received Nephrobiolic at 2 capsules 2 times a day for 1 month (5–7 days before surgery + 23–25 days after surgical treatment (pieholithotripsy)), with subsequent follow-up observation for 1 month. Results. The passage of stone fragments after retrograde intrarenal surgery (RIRS) was more effectively observed in the group receiving Nephrobiolic. When assessing the level of urine enzymes (alkaline phosphatase (ALP), lactate dehydrogenase (LDH), gamma-glutamyltransferase (GGT), and leucine aminopeptidase (LAP)) in all patients after lithotripsy, an increase in enzymeuria was noted in both groups, more pronounced in group 1, indicating damage to the kidney cell membranes due to the surgical intervention. When assessing the level of enzymuria in the remote period, in the 2nd group of patients this indicator returned to baseline (pre-intervention) values, in the 1st group – a moderate increase in the level of enzymuria persisted. Conclusion. Nephrobiolic promotes a more effective and less painful expulsion of stone fragments after retrograde pyelolithotripsy. This phytocomplex is capable of protecting kidney tissue from the damaging effects of lithotripsy and is characterized by a high degree of safety, which is very important during nephroprotective and lithokinetic therapy.
- 10 October 2025
- Published by ECO-Vector LLC in Urology Reports (St. - Petersburg)
- Vol. 15 (3) , 307-313
Modern approaches to phytotherapy in uric acid nephrolithiasis
The article discusses pathogenetic and clinical aspects of phytotherapy in patients with urolithiasis. Phytotherapy plays an important role in the treatment and metaphylaxis of uric acid nephrolithiasis. This is attributed to its efficacy and safety, including during long-term use. The article examines currently available herbal formulations with proven clinical efficacy. Herbal formulations used in patients with uric acid nephrolithiasis typically include components such as extracts of Java tea leaves (Orthosiphon stamineus), Alpinia officinarum, field horsetail, and the roots and rhizomes of Levisticum officinale. These plants are well known for their beneficial properties and have long been used in traditional medicine. The active ingredients of these herbal formulations, such as saponins, flavonoids, terpenes, fatty acids, phenolic glycosides, caffeic acid metabolites (rosmarinic and lithospermic acids), tannins, and vitamins (notably, ascorbic acid is present in all the products mentioned), have a significant impact on their therapeutic effect. The herbal formulations exhibit diuretic, anti-inflammatory, antibacterial, and antispasmodic properties. The development of new, effective herbal formulations for the treatment of uric acid nephrolithiasis, as well as the study of their therapeutic mechanisms, remain highly relevant in modern urology.
- 10 October 2025
- Published by ECO-Vector LLC in Urology Reports (St. - Petersburg)
- Vol. 15 (3) , 307-313
Modern approaches to phytotherapy in uric acid nephrolithiasis
The article discusses pathogenetic and clinical aspects of phytotherapy in patients with urolithiasis. Phytotherapy plays an important role in the treatment and metaphylaxis of uric acid nephrolithiasis. This is attributed to its efficacy and safety, including during long-term use. The article examines currently available herbal formulations with proven clinical efficacy. Herbal formulations used in patients with uric acid nephrolithiasis typically include components such as extracts of Java tea leaves (Orthosiphon stamineus), Alpinia officinarum, field horsetail, and the roots and rhizomes of Levisticum officinale. These plants are well known for their beneficial properties and have long been used in traditional medicine. The active ingredients of these herbal formulations, such as saponins, flavonoids, terpenes, fatty acids, phenolic glycosides, caffeic acid metabolites (rosmarinic and lithospermic acids), tannins, and vitamins (notably, ascorbic acid is present in all the products mentioned), have a significant impact on their therapeutic effect. The herbal formulations exhibit diuretic, anti-inflammatory, antibacterial, and antispasmodic properties. The development of new, effective herbal formulations for the treatment of uric acid nephrolithiasis, as well as the study of their therapeutic mechanisms, remain highly relevant in modern urology.
- 30 September 2025
- Published by ECO-Vector LLC in Urology Reports (St. - Petersburg)
- Vol. 15 (3) , 265-271
Robot-assisted abdominoperineal vesicourethral reanastomosis
BACKGROUND: Vesicourethral anastomotic stricture is a narrowing of the urethra at the junction between the membranous urethra and the bladder neck. This complication is reported in 4.8% of patients following radical prostatectomy, with an average time to vesicourethral anastomotic stricture formation of 3.4 months. Minimally invasive treatment modalities, such as urethral dilation, transurethral resection, and bladder neck incision, are frequently ineffective. Reconstructive surgery is currently considered the treatment of choice for recurrent vesicourethral anastomotic stricture. According to various authors, success rates of vesicourethral anastomotic reconstruction using perineal, abdominal, or abdominoperineal approaches can reach up to 100%. AIM: The work aimed to evaluate the outcomes of robot-assisted abdominoperineal vesicourethral reanastomosis in patients with recurrent vesicourethral anastomotic stricture. METHODS: The study analyzed treatment outcomes in seven patients with recurrent vesicourethral anastomotic stricture who underwent robot-assisted abdominoperineal vesicourethral reanastomosis. RESULTS: Six months postoperatively, there was a significant improvement in urinary outflow: Qmax increased from 1.8 [0; 3.6] at baseline to 13.4 [12.2; 14] mL/s, p = 0.0005. Furthermore, there was a marked reduction in lower urinary tract symptoms, with the total IPSS score decreasing from 23 [20.3; 25.8] to 9 [7.5; 11] (p = 0.0234), and an improvement in quality of life: QoL decreased from 6 [5; 6] to 2 [2; 2.5] (p = 0.0156). No patient experienced complications above Clavien–Dindo grade II. One (14.3%) patient developed de novo severe urinary incontinence, whereas two (28.6%) had persistent mild incontinence that existed prior to surgery. There were no additional interventions required during the postoperative period. CONCLUSION: Robot-assisted abdominoperineal vesicourethral reanastomosis is a safe and effective technique for the management of recurrent vesicourethral anastomotic stricture. This approach may be considered for patients with preserved continence and extensive strictures. Further studies are needed to assess long-term surgical outcomes.
- 30 September 2025
- Published by ECO-Vector LLC in Urology Reports (St. - Petersburg)
- Vol. 15 (3) , 265-271
Robot-assisted abdominoperineal vesicourethral reanastomosis
BACKGROUND: Vesicourethral anastomotic stricture is a narrowing of the urethra at the junction between the membranous urethra and the bladder neck. This complication is reported in 4.8% of patients following radical prostatectomy, with an average time to vesicourethral anastomotic stricture formation of 3.4 months. Minimally invasive treatment modalities, such as urethral dilation, transurethral resection, and bladder neck incision, are frequently ineffective. Reconstructive surgery is currently considered the treatment of choice for recurrent vesicourethral anastomotic stricture. According to various authors, success rates of vesicourethral anastomotic reconstruction using perineal, abdominal, or abdominoperineal approaches can reach up to 100%. AIM: The work aimed to evaluate the outcomes of robot-assisted abdominoperineal vesicourethral reanastomosis in patients with recurrent vesicourethral anastomotic stricture. METHODS: The study analyzed treatment outcomes in seven patients with recurrent vesicourethral anastomotic stricture who underwent robot-assisted abdominoperineal vesicourethral reanastomosis. RESULTS: Six months postoperatively, there was a significant improvement in urinary outflow: Qmax increased from 1.8 [0; 3.6] at baseline to 13.4 [12.2; 14] mL/s, p = 0.0005. Furthermore, there was a marked reduction in lower urinary tract symptoms, with the total IPSS score decreasing from 23 [20.3; 25.8] to 9 [7.5; 11] (p = 0.0234), and an improvement in quality of life: QoL decreased from 6 [5; 6] to 2 [2; 2.5] (p = 0.0156). No patient experienced complications above Clavien–Dindo grade II. One (14.3%) patient developed de novo severe urinary incontinence, whereas two (28.6%) had persistent mild incontinence that existed prior to surgery. There were no additional interventions required during the postoperative period. CONCLUSION: Robot-assisted abdominoperineal vesicourethral reanastomosis is a safe and effective technique for the management of recurrent vesicourethral anastomotic stricture. This approach may be considered for patients with preserved continence and extensive strictures. Further studies are needed to assess long-term surgical outcomes.
- Open Access
- 25 June 2025
- Published by UroMedia LLC in Experimental and Сlinical Urology
- Vol. 18 (2)
Prevention of postcoital cystitis.
Introduction. Postcoital cystitis, which has a chronic form, can be attributed to a type of chronic cystitis in women. In the absence of positive dynamics from behavioral therapy, herbal and antimicrobial drugs used before or after sexual intercourse to prevent exacerbation of postcoital cystitis, the priority is the use of complexes of substances that strengthen the immune system, improve the condition of the bladder mucosa and have an antimicrobial effect. Objective: to evaluate the efficacy and safety of the drug Nephronerei for the prevention of postcoital cystitis in women. Materials and methods. The study included 80 women with chronic postcoital cystitis, who were divided into two groups of 40 people depending on the treatment received: group – patients took Nephronerey once, 1 sachet after each sexual intercourse, and group 2 – patients took only herbal uroseptics. The observation period was 180 days. Results. It was found that the use of Nephronerey (1 sachet after each sexual contact) for six months significantly reduces the likelihood of relapses, reducing them threefold. Good tolerability of the drug, a noticeable decrease in the frequency of exacerbations and, as a result, a significant improvement in the quality of life of patients were noted. Conclusions. The drug Nephronerey can be recommended for the prevention of postcoital cystitis.
- 25 June 2025
- Published by UroMedia LLC in Experimental and Сlinical Urology
- Vol. 18 (2)
Open AccessPrevention of postcoital cystitis.
Introduction. Postcoital cystitis, which has a chronic form, can be attributed to a type of chronic cystitis in women. In the absence of positive dynamics from behavioral therapy, herbal and antimicrobial drugs used before or after sexual intercourse to prevent exacerbation of postcoital cystitis, the priority is the use of complexes of substances that strengthen the immune system, improve the condition of the bladder mucosa and have an antimicrobial effect. Objective: to evaluate the efficacy and safety of the drug Nephronerei for the prevention of postcoital cystitis in women. Materials and methods. The study included 80 women with chronic postcoital cystitis, who were divided into two groups of 40 people depending on the treatment received: group – patients took Nephronerey once, 1 sachet after each sexual intercourse, and group 2 – patients took only herbal uroseptics. The observation period was 180 days. Results. It was found that the use of Nephronerey (1 sachet after each sexual contact) for six months significantly reduces the likelihood of relapses, reducing them threefold. Good tolerability of the drug, a noticeable decrease in the frequency of exacerbations and, as a result, a significant improvement in the quality of life of patients were noted. Conclusions. The drug Nephronerey can be recommended for the prevention of postcoital cystitis.
- Open Access
- 2 March 2025
- Published by Rostov State Medical University in Urology Herald
- Vol. 13 (1) , 39-47
Erectile function rehabilitation with phosphodiesterase type 5 inhibitors in patients following nerve-sparing radical prostatectomy: a comparative efficacy analysis of different course lengths
Introduction. Despite the selective patient screening and improvements in surgical techniques for radical prostatectomy (RP), the incidence of erectile dysfunction (ED) remains relatively high. The efficacy of phosphodiesterase type 5 inhibitors (PDE5i) in patients undergoing nerve-sparing RP can vary from 35% to 75%. One of the issues in penile rehabilitation after RP is its duration. Currently, there are no standardised guidelines on the length of PDE5i therapy, with authors providing conflicting and insufficient data to recommend specific timelines for penile rehabilitation. Therefore, further research is required to determine the optimal duration of PDE5i-based rehabilitation.Objective. To compare the efficacy of long-term PDE-5i administration for restoring erectile function in patients undergoing nerve-sparing RP versus a short 3-month course in the early postoperative period.Materials & methods. A prospective analysis of data from 81 patients with localized prostate cancer who underwent laparoscopic nerve-sparing RP was carried out. In the postoperative period, patients were divided into two groups using simple randomisation. Group 1 received PDE5i for 11 months as part of penile rehabilitation, while group 2 received them for three months.Results. The severity of ED three- and 12-months following RP was comparable in both groups. A long-term course of PDE-5i showed no advantages at the one-year stage of the study in terms of erectile function compared to a threemonth therapy course. The same trend was observed in the results of the nocturnal penile tumescence test. In addition to developing irreversible ED, gradual penile shortening after surgery can cause the patient's inability to urinate while standing and, as a result, lead to serious psychological problems. When assessing the penile length in both groups, a tendency towards its shortening at the annual stage of the study was noted, which indicates insufficient effectiveness of both the annual and three-month rehabilitation course with PDE-5i.Conclusion. Long-term use of PDE-5i compared to a short-term rehabilitation course did not demonstrate any advantages in restoring erectile function one year following nerve-sparing RP.
- 2 March 2025
- Published by Rostov State Medical University in Urology Herald
- Vol. 13 (1) , 39-47
Open AccessErectile function rehabilitation with phosphodiesterase type 5 inhibitors in patients following nerve-sparing radical prostatectomy: a comparative efficacy analysis of different course lengths
Introduction. Despite the selective patient screening and improvements in surgical techniques for radical prostatectomy (RP), the incidence of erectile dysfunction (ED) remains relatively high. The efficacy of phosphodiesterase type 5 inhibitors (PDE5i) in patients undergoing nerve-sparing RP can vary from 35% to 75%. One of the issues in penile rehabilitation after RP is its duration. Currently, there are no standardised guidelines on the length of PDE5i therapy, with authors providing conflicting and insufficient data to recommend specific timelines for penile rehabilitation. Therefore, further research is required to determine the optimal duration of PDE5i-based rehabilitation.Objective. To compare the efficacy of long-term PDE-5i administration for restoring erectile function in patients undergoing nerve-sparing RP versus a short 3-month course in the early postoperative period.Materials & methods. A prospective analysis of data from 81 patients with localized prostate cancer who underwent laparoscopic nerve-sparing RP was carried out. In the postoperative period, patients were divided into two groups using simple randomisation. Group 1 received PDE5i for 11 months as part of penile rehabilitation, while group 2 received them for three months.Results. The severity of ED three- and 12-months following RP was comparable in both groups. A long-term course of PDE-5i showed no advantages at the one-year stage of the study in terms of erectile function compared to a threemonth therapy course. The same trend was observed in the results of the nocturnal penile tumescence test. In addition to developing irreversible ED, gradual penile shortening after surgery can cause the patient's inability to urinate while standing and, as a result, lead to serious psychological problems. When assessing the penile length in both groups, a tendency towards its shortening at the annual stage of the study was noted, which indicates insufficient effectiveness of both the annual and three-month rehabilitation course with PDE-5i.Conclusion. Long-term use of PDE-5i compared to a short-term rehabilitation course did not demonstrate any advantages in restoring erectile function one year following nerve-sparing RP.